Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma

Motoi Kondo, Hirofumi Yamamoto, Hiroaki Nagano, Jiro Okami, Yasuhiro Ito, Junzo Shimizu, Hidetoshi Eguchi, Atsushi Miyamoto, Keizo Dono, Koji Umeshita, Nariaki Matsuura, Ken Ichi Wakasa, Shoji Nakamori, Masato Sakon, Morito Monden

Research output: Contribution to journalArticle

167 Citations (Scopus)

Abstract

Recent studies have shown increased levels of cyclooxygenase-2 (COX-2) in a variety of human malignancies including hepatocellular carcinoma (HCC), but little is known about the prognostic value of COX-2 in HCC or its associated nontumor liver tissue. We examined the expression of COX-2 protein by immunohistochemistry in 53 patients with HCCs whose corresponding nontumor tissues were hepatitis C virus-related chronic hepatitis (n = 21) and cirrhosis (n = 32). Samples of nine histologically normal livers and eight precancerous dysplasias were also analyzed. The level of COX-2 increased from normal liver to chronic hepatitis to cirrhosis. The majority of cirrhotic livers (81%) displayed marked COX-2 expression. In dysplasias, COX-2 expression was mainly moderate or strong (88%). In HCC, 17% of samples displayed a high COX-2 expression, and 37% of samples expressed COX-2 at a moderate level. Concordant results were obtained with reverse transcription- PCR and Western blot analyses. Clinicopathological survey indicated a significant correlation between COX-2 expression and differentiated carcinoma (P = 0.019). Although there was no correlation between COX-2 expression in HCC and prognosis, a striking difference was found between COX-2 expression in nontumor tissue and shorter disease-free survival (P = 0.0132). Moreover, high COX-2 expression in nontumor tissue was significantly correlated with the presence of active inflammation (P < 0.0001). The present findings suggest that COX-2 expression in nontumor tissue may play a positive role in relapse of HCC after surgery.

Original languageEnglish
Pages (from-to)4005-4012
Number of pages8
JournalClinical Cancer Research
Volume5
Issue number12
Publication statusPublished - Dec 1 1999
Externally publishedYes

Fingerprint

Cyclooxygenase 2
Disease-Free Survival
Hepatocellular Carcinoma
Liver
Chronic Hepatitis
Fibrosis
Hepacivirus
Reverse Transcription
Western Blotting
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kondo, M., Yamamoto, H., Nagano, H., Okami, J., Ito, Y., Shimizu, J., ... Monden, M. (1999). Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clinical Cancer Research, 5(12), 4005-4012.

Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. / Kondo, Motoi; Yamamoto, Hirofumi; Nagano, Hiroaki; Okami, Jiro; Ito, Yasuhiro; Shimizu, Junzo; Eguchi, Hidetoshi; Miyamoto, Atsushi; Dono, Keizo; Umeshita, Koji; Matsuura, Nariaki; Wakasa, Ken Ichi; Nakamori, Shoji; Sakon, Masato; Monden, Morito.

In: Clinical Cancer Research, Vol. 5, No. 12, 01.12.1999, p. 4005-4012.

Research output: Contribution to journalArticle

Kondo, M, Yamamoto, H, Nagano, H, Okami, J, Ito, Y, Shimizu, J, Eguchi, H, Miyamoto, A, Dono, K, Umeshita, K, Matsuura, N, Wakasa, KI, Nakamori, S, Sakon, M & Monden, M 1999, 'Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma', Clinical Cancer Research, vol. 5, no. 12, pp. 4005-4012.
Kondo, Motoi ; Yamamoto, Hirofumi ; Nagano, Hiroaki ; Okami, Jiro ; Ito, Yasuhiro ; Shimizu, Junzo ; Eguchi, Hidetoshi ; Miyamoto, Atsushi ; Dono, Keizo ; Umeshita, Koji ; Matsuura, Nariaki ; Wakasa, Ken Ichi ; Nakamori, Shoji ; Sakon, Masato ; Monden, Morito. / Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 12. pp. 4005-4012.
@article{8e00da8389854ab2a575b990c66b96db,
title = "Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma",
abstract = "Recent studies have shown increased levels of cyclooxygenase-2 (COX-2) in a variety of human malignancies including hepatocellular carcinoma (HCC), but little is known about the prognostic value of COX-2 in HCC or its associated nontumor liver tissue. We examined the expression of COX-2 protein by immunohistochemistry in 53 patients with HCCs whose corresponding nontumor tissues were hepatitis C virus-related chronic hepatitis (n = 21) and cirrhosis (n = 32). Samples of nine histologically normal livers and eight precancerous dysplasias were also analyzed. The level of COX-2 increased from normal liver to chronic hepatitis to cirrhosis. The majority of cirrhotic livers (81{\%}) displayed marked COX-2 expression. In dysplasias, COX-2 expression was mainly moderate or strong (88{\%}). In HCC, 17{\%} of samples displayed a high COX-2 expression, and 37{\%} of samples expressed COX-2 at a moderate level. Concordant results were obtained with reverse transcription- PCR and Western blot analyses. Clinicopathological survey indicated a significant correlation between COX-2 expression and differentiated carcinoma (P = 0.019). Although there was no correlation between COX-2 expression in HCC and prognosis, a striking difference was found between COX-2 expression in nontumor tissue and shorter disease-free survival (P = 0.0132). Moreover, high COX-2 expression in nontumor tissue was significantly correlated with the presence of active inflammation (P < 0.0001). The present findings suggest that COX-2 expression in nontumor tissue may play a positive role in relapse of HCC after surgery.",
author = "Motoi Kondo and Hirofumi Yamamoto and Hiroaki Nagano and Jiro Okami and Yasuhiro Ito and Junzo Shimizu and Hidetoshi Eguchi and Atsushi Miyamoto and Keizo Dono and Koji Umeshita and Nariaki Matsuura and Wakasa, {Ken Ichi} and Shoji Nakamori and Masato Sakon and Morito Monden",
year = "1999",
month = "12",
day = "1",
language = "English",
volume = "5",
pages = "4005--4012",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma

AU - Kondo, Motoi

AU - Yamamoto, Hirofumi

AU - Nagano, Hiroaki

AU - Okami, Jiro

AU - Ito, Yasuhiro

AU - Shimizu, Junzo

AU - Eguchi, Hidetoshi

AU - Miyamoto, Atsushi

AU - Dono, Keizo

AU - Umeshita, Koji

AU - Matsuura, Nariaki

AU - Wakasa, Ken Ichi

AU - Nakamori, Shoji

AU - Sakon, Masato

AU - Monden, Morito

PY - 1999/12/1

Y1 - 1999/12/1

N2 - Recent studies have shown increased levels of cyclooxygenase-2 (COX-2) in a variety of human malignancies including hepatocellular carcinoma (HCC), but little is known about the prognostic value of COX-2 in HCC or its associated nontumor liver tissue. We examined the expression of COX-2 protein by immunohistochemistry in 53 patients with HCCs whose corresponding nontumor tissues were hepatitis C virus-related chronic hepatitis (n = 21) and cirrhosis (n = 32). Samples of nine histologically normal livers and eight precancerous dysplasias were also analyzed. The level of COX-2 increased from normal liver to chronic hepatitis to cirrhosis. The majority of cirrhotic livers (81%) displayed marked COX-2 expression. In dysplasias, COX-2 expression was mainly moderate or strong (88%). In HCC, 17% of samples displayed a high COX-2 expression, and 37% of samples expressed COX-2 at a moderate level. Concordant results were obtained with reverse transcription- PCR and Western blot analyses. Clinicopathological survey indicated a significant correlation between COX-2 expression and differentiated carcinoma (P = 0.019). Although there was no correlation between COX-2 expression in HCC and prognosis, a striking difference was found between COX-2 expression in nontumor tissue and shorter disease-free survival (P = 0.0132). Moreover, high COX-2 expression in nontumor tissue was significantly correlated with the presence of active inflammation (P < 0.0001). The present findings suggest that COX-2 expression in nontumor tissue may play a positive role in relapse of HCC after surgery.

AB - Recent studies have shown increased levels of cyclooxygenase-2 (COX-2) in a variety of human malignancies including hepatocellular carcinoma (HCC), but little is known about the prognostic value of COX-2 in HCC or its associated nontumor liver tissue. We examined the expression of COX-2 protein by immunohistochemistry in 53 patients with HCCs whose corresponding nontumor tissues were hepatitis C virus-related chronic hepatitis (n = 21) and cirrhosis (n = 32). Samples of nine histologically normal livers and eight precancerous dysplasias were also analyzed. The level of COX-2 increased from normal liver to chronic hepatitis to cirrhosis. The majority of cirrhotic livers (81%) displayed marked COX-2 expression. In dysplasias, COX-2 expression was mainly moderate or strong (88%). In HCC, 17% of samples displayed a high COX-2 expression, and 37% of samples expressed COX-2 at a moderate level. Concordant results were obtained with reverse transcription- PCR and Western blot analyses. Clinicopathological survey indicated a significant correlation between COX-2 expression and differentiated carcinoma (P = 0.019). Although there was no correlation between COX-2 expression in HCC and prognosis, a striking difference was found between COX-2 expression in nontumor tissue and shorter disease-free survival (P = 0.0132). Moreover, high COX-2 expression in nontumor tissue was significantly correlated with the presence of active inflammation (P < 0.0001). The present findings suggest that COX-2 expression in nontumor tissue may play a positive role in relapse of HCC after surgery.

UR - http://www.scopus.com/inward/record.url?scp=17044453428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17044453428&partnerID=8YFLogxK

M3 - Article

VL - 5

SP - 4005

EP - 4012

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 12

ER -